» Articles » PMID: 28596674

Follow-up After Curative Resection for Gastric Cancer: Is It Time to Tailor It?

Overview
Specialty Gastroenterology
Date 2017 Jun 10
PMID 28596674
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

There is still no consensus on the follow-up frequency and regimen after curative resection for gastric cancer. Moreover, controversy exists regarding the utility of follow-up in improving survival, and the recommendations of experts and societies vary considerably. The main reason to establish surveillance programs is to diagnose tumor recurrence or metachronous cancers early and to thereby provide prompt treatment and prolong survival. In the setting of gastric malignancies, other reasons have been put forth: (1) the detection of adverse effects of a previous surgery, such as malnutrition or digestive sequelae; (2) the collection of data; and (3) the identification of psychological and/or social problems and provision of appropriate support to the patients. No randomized controlled trials on the role of follow-up after curative resection of gastric carcinoma have been published. Herein, the primary retrospective series and systematic reviews on this subject are analyzed and discussed. Furthermore, the guidelines from international and national scientific societies are discussed. Follow-up is recommended by the majority of institutions; however, there is no real evidence that follow-up can improve long-term survival rates. Several studies have demonstrated that it is possible to stratify patients submitted to curative gastrectomy into different classes according to the risk of recurrence. Furthermore, promising studies have identified several molecular markers that are related to the risk of relapse and to prognosis. Based on these premises, a promising strategy will be to tailor follow-up in relation to the patient and tumor characteristics, molecular marker status, and individual risk of recurrence.

Citing Articles

Impact of Routine Follow-Ups After Curative Gastrectomy in Elderly Patients with Early Gastric Cancer.

Yoo J, Ko C, Jeong S, Oh S, Seong B, Yook J Ann Surg Oncol. 2024; 32(4):2629-2636.

PMID: 39739264 DOI: 10.1245/s10434-024-16713-8.


Molecular Classifications in Gastric Cancer: A Call for Interdisciplinary Collaboration.

Diaz Del Arco C, Fernandez Acenero M, Ortega Medina L Int J Mol Sci. 2024; 25(5).

PMID: 38473896 PMC: 10931799. DOI: 10.3390/ijms25052649.


Smoking as a Risk Factor for Very Late Recurrence in Surgically Resected Early-Stage Primary Hepatocellular Carcinoma.

Cho W, Wang C, Tsai M, Lin C, Yen Y, Chen C Clin Med Insights Oncol. 2024; 18:11795549241228232.

PMID: 38450293 PMC: 10916494. DOI: 10.1177/11795549241228232.


Overall Survival Following Anastomotic Leakage After Surgery for Carcinoma of the Esophagus and Gastroesophageal Junction: A Systematic Review.

Pace M, Minervini A, Goglia M, Cinquepalmi M, Moschetta G, Antolino L In Vivo. 2023; 37(4):1423-1431.

PMID: 37369467 PMC: 10347909. DOI: 10.21873/invivo.13226.


Breath Volatile Organic Compounds in Surveillance of Gastric Cancer Patients following Radical Surgical Management.

Skapars R, Gasenko E, Broza Y, Sivins A, Polaka I, Bogdanova I Diagnostics (Basel). 2023; 13(10).

PMID: 37238155 PMC: 10216977. DOI: 10.3390/diagnostics13101670.


References
1.
Matboli M, El-Nakeep S, Hossam N, Habieb A, Azazy A, Ebrahim A . Exploring the role of molecular biomarkers as a potential weapon against gastric cancer: A review of the literature. World J Gastroenterol. 2016; 22(26):5896-908. PMC: 4948264. DOI: 10.3748/wjg.v22.i26.5896. View

2.
Jeon B, Choi M, Lee J, Noh S . Relationships between gastrointestinal symptoms, uncertainty, and perceived recovery in patients with gastric cancer after gastrectomy. Nurs Health Sci. 2015; 18(1):23-9. DOI: 10.1111/nhs.12219. View

3.
Oba K, Paoletti X, Bang Y, Bleiberg H, Burzykowski T, Fuse N . Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis. Eur J Cancer. 2013; 49(7):1565-77. DOI: 10.1016/j.ejca.2012.12.016. View

4.
Fujiya K, Tokunaga M, Makuuchi R, Nishiwaki N, Omori H, Takagi W . Early detection of nonperitoneal recurrence may contribute to survival benefit after curative gastrectomy for gastric cancer. Gastric Cancer. 2016; 20(Suppl 1):141-149. DOI: 10.1007/s10120-016-0661-x. View

5.
Tsai M, Wang C, Tsai C, Huang H, Chi H, Lin Y . Potential Diagnostic, Prognostic and Therapeutic Targets of MicroRNAs in Human Gastric Cancer. Int J Mol Sci. 2016; 17(6). PMC: 4926478. DOI: 10.3390/ijms17060945. View